



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity

Ryo C. Yanagita^a, Hiroaki Kamachi^a, Keisuke Tanaka^a, Akira Murakami^a, Yu Nakagawa^b, Harukuni Tokuda^c, Hiroshi Nagai^d, Kazuhiro Irie^{a,*}

^a Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan

^b Synthetic Cellular Chemistry Laboratory, Advanced Science Institute, RIKEN (The Institute of Physical and Chemical Research), Wako 351-0198, Japan

^c Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan

^d Tokyo University of Marine Science and Technology, Minato-ku, Tokyo 108-8477, Japan

ARTICLE INFO

Article history:

Received 3 July 2010

Revised 10 August 2010

Accepted 11 August 2010

Available online 13 August 2010

Keywords:

Protein kinase C

Tumor promoter

Bryostatin

Antiproliferative

Epstein-Barr virus

Aplysiatoxin

Phorbol ester

ABSTRACT

The 18-deoxy derivative (**3**) of a simplified analogue (**1**) of aplysiatoxin with antiproliferative activity was synthesized to examine the role of the phenolic hydroxyl group at position 18 in the biological activities of **1**. Compound **3** as well as **1** showed significant affinity for protein kinase C δ (PKC δ), and the antiproliferative activity of **3** was slightly higher than that of **1**. However, the anti-tumor-promoting activity of **3** was less than that of **1** in vitro, suggesting that the phenolic hydroxyl group of **1** is necessary for the anti-tumor-promoting activity but not for the binding of PKC δ and antiproliferative activity. Moreover, PKC isozyme selectivity of **3** was similar to that of **1**, suggesting non-PKC receptors for these compounds to play some roles in the anti-tumor-promoting activity of **1**.

© 2010 Elsevier Ltd. All rights reserved.

Protein kinase C (PKC) isozymes are serine/threonine kinases involved in cell proliferation, differentiation, and apoptosis.^{1,2} The PKC family comprises at least eleven members of three distinct types: conventional (α , β I, β II, and γ), novel (δ , ϵ , η , and θ), and atypical (λ /I and ζ) PKCs.³ Naturally-occurring PKC activators such as 12-O-tetradecanoylphorbol 13-acetate (TPA),⁴ teleocidin B-4,⁵ and aplysiatoxin⁶ (ATX; Fig. 1) bind to tandem C1 domains (C1A and C1B) in the regulatory region of conventional and novel PKCs. While these activators exhibit strong tumor-promoting activity,⁵ bryostatin 1⁷ (bryo-1; Fig. 1), a PKC activator isolated from the marine bryozoan *Bugula neritina*, shows significant anticancer and anti-tumor-promoting activities possibly through PKC δ -dependent mechanisms.^{8–10} Bryo-1 has also attracted attention as a therapeutic lead for the treatment of central nervous system (CNS) diseases such as Alzheimer's disease and depression.¹¹ Despite its fascinating activities, however, bryo-1's low availability from natural sources and structural complexity have hampered its optimization for therapeutic use.

Several studies have indicated that the hydrophobicity of PKC activators is a critical determinant for tumor-promoting activity. For example, while hydrophobic phorbol esters such as 12-O-

tetradecanoylphorbol 13-acetate (TPA) showed strong tumor-promoting activity,⁵ less hydrophobic derivatives such as 12-deoxyphorbol 13-phenylacetate,¹² prostratin (12-deoxyphorbol 13-acetate),¹³ phorbol 12,13-diacetate,¹⁴ and PDBu¹⁵ showed anti-tumor-promoting activity in vivo. Moreover, loss of the bromine atom of aplysiatoxin did not affect the affinity for PKC but reduced the tumor-promoting activity of ATX.¹⁶ Based on these findings, we recently developed simplified analogues of ATX (**1** and **2**; Fig. 1) with less hydrophobicity and stereogenic centers, showing bryo-1-like activity.¹⁷ Compound **1** was produced in only 22 steps, three times less than is needed to produce bryo-1, and showed antiproliferative effects against many human cancer cell lines comparable to bryo-1. Moreover, **1** showed very weak tumor-promoting activity, but significant anti-tumor-promoting activity, in vitro. However, its affinity for the C1B domain of PKC δ (δ -C1B) and ability to activate the PKC δ isozyme were one order of magnitude lower than those of bryo-1.

In that study, we also suggested the geminal dimethyl group at position 6 and/or the phenolic hydroxyl group at position 18 of **1** to be important both for the binding of PKC δ and for the antiproliferative activity.¹⁷ However, the exact role of the phenolic hydroxyl group in these activities remains unknown. In this communication, we report the synthesis and biological activities of the 18-deoxy analogue (**3**) of **1**.

* Corresponding author. Tel.: +81 75 753 6281; fax: +81 75 753 6284.

E-mail address: irie@kais.kyoto-u.ac.jp (K. Irie).




Figure 1. Structure of bryostatin 1 (bryo-1), alysiatoxin (ATX), and the simplified analogues of ATX (1–3).

Compound **3** was synthesized from **1** with a transfer-hydrogenation method (Scheme 1). Selective triflation of the phenolic hydroxyl group followed by transfer-hydrogenation using palladium(II) acetate, formic acid, and triethylamine gave **3**.¹⁸ The affinity of **3** for the C1 domains of PKC δ was evaluated by inhibiting the specific binding of [³H]phorbol 12,13-dibutyrate (PDBu) to the synthetic PKC δ C1 peptides (δ -C1A, δ -C1B) as described previously.¹⁹ The affinity of **3** for these peptides was almost equal to that of **1** (Table 1) and was significantly greater than that of **2**, suggesting the geminal dimethyl group at position 6, not the phenolic hydroxyl group at position 18 of **1**, to play an important role in the binding to the C1 domains. It is worth noting that the removal of the hydrophilic phenolic hydroxyl group from the side chain of **1** did not affect the binding of PKC δ . This indicates that the side chain of these ATX analogues (**1** and **3**) is not a pharmacophore equivalent to the ester side chains of phorbol esters such as TPA that insert into phospholipid membranes. Since the introduction of oxygen or hydrophilic groups into the ester side chains of phorbol esters abolished the binding to PKC, the structure–activity data on **1** and **3** are not consistent with the pharmacophore model proposed previously based on computational methods.²⁰ However, the hydrophobicity of the PKC activators are important for the binding to PKC. The alkyl chain and the hydrophobic part of the benzene ring of the side chain of the analogues could contribute as the hydrophobic moiety such as the terpene moiety of teleocidin B-4 without a straight alkyl chain.

One important biological property of **1** is its antiproliferative activity. We evaluated the antiproliferative activity of **3** against a panel of 39 human cancer cell lines as described previously.²¹ The growth inhibitory activity is expressed as the concentration required to inhibit cell growth by 50% compared to an untreated control [GI₅₀ (M)]. The results for the cell lines in which **1** and **3** showed GI₅₀ values greater than each full panel mean-graph midpoint (MG-MID) are listed in Table 2; the MG-MID values of **1** and **3** were –4.98 and –5.09, respectively. The rest are provided as Supplementary data. The antiproliferative activities of **3** were equivalent to or higher than those of **1** except for the LOX-IMVI

Table 1

K_i values for the inhibition of [³H]PDBu's binding by **1–3** and ATX

PKC C1 peptides	K _i (nM)				K _d (nM) PDBu ^a
	1	2	3	ATX	
α -C1A	63 (5) ^b	2400 (100)	120 (10)	0.40 (0.05)	1.1
β -C1A	89 (5)	3500 (400)	140 (20)	0.45 (0.08)	1.3
γ -C1A	39 (3)	1600 (200)	80 (2)	0.63 (0.14)	1.5
δ -C1A	140 ^c	6800 ^c	130 (30)	12 ^c	51.9
δ -C1B	7.4 ^c	170 ^c	9.8 (0.5)	0.41 ^c	0.53
ϵ -C1B	25 (2)	820 (80)	37 (5)	1.3 (0.2)	0.81
η -C1B	4.4 (0.2)	180 (20)	12 (2)	0.36 (0.02)	0.45
θ -C1B	4.0 (0.5)	170 (20)	8.1 (1.0)	0.16 (0.03)	0.72

^a Cited from Ref. 28.

^b Standard deviation from triplicate experiments.

^c Cited from Ref. 17.

Table 2

log GI₅₀ values for **1** and **3** against a subset of 39 human cancer cell lines

Cancer type	Cell line	log GI ₅₀ (log M)		
		1 ^a	3	Bryo-1 ^b
Breast	HBC-4	–6.33	–6.28	NR ^c
Breast	BSY-1	–4.87	–5.17	NR
Breast	MDA-MB-231	–5.61	–5.67	–5.20
CNS	SF-295	–5.06	–5.14	–5.20
Colon	HCC2998	–5.43	–5.53	–5.30
Lung	NCI-H460	–5.60	–5.83	–5.60
Lung	A549	–5.32	–5.49	–5.20
Melanoma	LOX-IMVI	–5.74	–5.17	NR
Stomach	St-4	–5.55	–6.05	NR
Stomach	MKN45	–5.33	–6.09	NR
Prostate	PC-3	–4.96	–5.26	–5.30

^a Cited from Ref. 17. Antiproliferative assays of **1** and **3** were carried out simultaneously by the same method.


^b Cited from Ref. 22. Antiproliferative assay of bryo-1 could not be carried out since the supply of bryo-1 is extremely limited.

^c Not reported.

melanoma cell lines. Notably, the GI₅₀ values of **3** against St-4 and MKN45 stomach cancer cells were below 10^{–6} M. Since the affinity of **3** for PKC δ was almost equal to that of **1**, the slight increase in the antiproliferative activity of **3** might be due to the increase in hydrophobicity associated with the ability of the molecule to permeate membranes.

As mentioned above, the hydrophobicity of the PKC activators is a critical determinant for tumor-promoting activity. The tumor-promoting/anti-tumor-promoting activity of **3** was estimated by the Epstein-Barr virus early antigen (EBV-EA) induction test using Raji cell (EBV genome-carrying lymphoblastoid cell) as described previously.²³

As shown in Figure 2, the ability to induce EA of each compound at 10^{–7} M was measured since potent tumor promoters such as



Scheme 1. Synthesis of **3**. Reagents and conditions: (a) *N*-phenyl triflimide, Et₃N, CH₂Cl₂ (91%); (b) Pd(OAc)₂, Ph₃P, Et₃N, HCO₂H, DMF (25%).




Figure 2. EBV-EA-inducing ability of TPA, ATX, bryo-1, **1**, and **3**. Percentages of EA-positive cells are shown. Sodium *n*-butyrate (4 mM) was added to all samples to enhance the sensitivity of Raji cells. Only 0.1% EA-induction was demonstrated at 4 mM. The final concentration of dimethyl sulfoxide (DMSO) was 0.4%. Cell viability exceeded 60% in each experiment except for ATX (50%). Error bars represent standard errors of the mean ($n = 3$).

TPA and teleocidin B-4 induced maximal EA induction (ca. 30%) at 10^{-7} – 10^{-8} M.^{24,25} Quite similar induction was observed at 10^{-6} M (Supplementary data). TPA and ATX showed strong (28.8% and 18.4%) EA-inducing ability at 10^{-7} M, while bryo-1 with little tumor-promoting activity at the same concentration showed weak induction (1.4%) and suppressed the EA-induction by TPA significantly (6.8%). In the case of the simplified ATX analogues, **3** showed weak EA-inducing ability (9.7%), which was equivalent to that of **1** (9.4%). However, the ability of **3** to suppress the EA-induction by TPA (15.2%) was lower than that of **1** (10.1%). These results suggest that the phenolic hydroxyl group at position 18 of **1** plays an important role in the anti-tumor-promoting ability rather than in the antiproliferative activity in vitro.

Not only PKC δ but also other PKC isozymes (PKCs) play important physiological roles, for example, Raji cells express PKC α , β II, and δ isozymes.^{26,27} To investigate the mode of action of the ATX analogues, PKC isozyme selectivity of ATX and its analogues were examined using the synthetic PKC C1 peptides. Recent investigation suggested that C1A domains in conventional PKCs and C1B domains in novel PKCs play critical roles in the activation of PKCs by the PKC activators.^{19,28} The affinities were, thus, measured by the C1A peptides of conventional PKCs and the C1B peptides of novel PKCs. The results are summarized in Table 1. While ATX showed little selectivity between conventional and novel PKCs like PDBu,²⁸ affinities of **1**–**3** for novel PKCs were about ten times higher than those for conventional PKC. Given that the affinity and the selectivity for PKC isozymes of **3** were comparable to those of **1**, these results also suggest an unknown receptor of **1** other than PKCs to be responsible for the anti-tumor-promoting ability of **1**.

In summary, we synthesized the 18-deoxy derivative (**3**) of a simplified analogue of ATX (**1**) to investigate the effect of the phenolic hydroxyl group at position 18 on the affinity for PKC δ , antiproliferative activity in 39 human cancer cell lines, and tumor-promoting/anti-tumor-promoting activity in vitro. Although **1** and **3** were almost the same in terms of binding to PKC isozymes including PKC δ , PKC isozyme selectivity, and antiproliferative activity, they differed significantly in the EBV-EA induction test with **3** showing less anti-tumor-promoting activity than **1**. The present results indicate that the phenolic hydroxyl group at position 18 is not involved in the antiproliferative activity of **1** in vitro. This means that the phenolic hydroxyl group would be available as a tunable site to develop superior analogues and molecular probes for analyzing the mechanism of the antiproliferative and anti-tumor-promoting activity of **1**.

Acknowledgments

This work was partly supported by The Naito Foundation and The Uehara Memorial Foundation (K.I.), and by a Grant-in-aid for Scientific Research (A) (No.21248015) (K.I.) and a Grant-in-aid for JSPS Fellows (No. 20-4135) (R.C.Y.) from The Ministry of Education, Culture, Sports, Science and Technology, Japan. Finally, we thank the Screening Committee of Anticancer Drugs supported by a Grant-in-aid for Scientific Research on the Priority Area 'Cancer' from The Ministry of Education, Culture, Sports, Science and Technology, Japan.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.bmcl.2010.08.051.

References and notes

- Nishizuka, Y. *Nature* **1984**, *308*, 693.
- Nishizuka, Y. *FASEB J.* **1995**, *9*, 484.
- Newton, A. C. *J. Biol. Chem.* **1995**, *270*, 28495.
- Hecker, E. *Naturwissenschaften* **1967**, *54*, 282.
- (a) Nakata, H.; Harada, H.; Hirata, Y. *Tetrahedron Lett.* **1966**, *23*, 2515; (b) Fujiki, H.; Sugimura, T. *Adv. Cancer Res.* **1987**, *49*, 223.
- Kato, Y.; Scheuer, P. J. *J. Am. Chem. Soc.* **1974**, *96*, 2245.
- Pettit, G. R.; Herald, C. L.; Doubek, D. L.; Herald, D. L.; Arnold, E.; Clardy, J. *J. Am. Chem. Soc.* **1982**, *104*, 6846.
- Hennings, H.; Blumberg, P. M.; Pettit, G. R.; Herald, C. L.; Shores, R.; Yuspa, S. H. *Carcinogenesis* **1987**, *8*, 1343.
- Gschwendt, M.; Fürstenberger, G.; Rose-John, S.; Rogers, M.; Kittstein, W.; Pettit, G. R.; Herald, C. L.; Marks, F. *Carcinogenesis* **1988**, *9*, 555.
- Hale, K. J.; Hummersone, M. G.; Manaviazar, S.; Frigerio, M. *Nat. Prod. Rep.* **2002**, *19*, 413.
- Sun, M. K.; Alkon, D. L. *CNS Drug Rev.* **2006**, *12*, 1.
- Szallasi, Z.; Krsmanovic, L.; Blumberg, P. M. *Cancer Res.* **1993**, *53*, 2507.
- Szallasi, Z.; Blumberg, P. M. *Cancer Res.* **1991**, *51*, 5355.
- Czerniecki, B.; Gad, S. C.; Reilly, C.; Smith, A. C.; Witz, G. *Carcinogenesis* **1986**, *7*, 1637.
- Moore, R. E. In *Cellular Interactions by Environmental Tumor Promoters*; Fujiki, H., Hecker, E., Moore, R. E., Sugimura, T., Weinstein, I. B., Eds.; Japan Scientific Society Press/VNU Science Press: Tokyo/Utrecht, 1984; pp 49–57.
- Fujiki, H.; Sugimura, T. In *Cancer Survey*; Slaga, T. J., Montesano, R., Eds.; Oxford University Press: London, 1984; Vol. 2, pp 539–556.
- Nakagawa, Y.; Yanagita, R. C.; Hamada, N.; Murakami, A.; Takahashi, H.; Saito, N.; Nagai, H.; Irie, K. *J. Am. Chem. Soc.* **2009**, *131*, 7573.
- Compound **3**: ¹H NMR (500 MHz, CDCl₃, 0.022 M, 296 K) δ 0.86 (3H, s), 0.98 (3H, s), 1.34–1.69 (13H, m), 2.21 (1H, t, $J = 6.0$ Hz), 2.40 (1H, dd, $J = 13.1$, 10.8 Hz), 2.49 (1H, d, $J = 15.6$ Hz), 2.53 (1H, dd, $J = 13.1$, 2.7 Hz), 2.62 (2H, t, $J = 7.8$ Hz), 2.70 (1H, dd, $J = 16.7$, 3.4 Hz), 2.80 (1H, dd, $J = 16.7$, 11.5 Hz), 3.70 (1H, quintet, $J = 5.7$ Hz), 3.77 (1H, ddd, $J = 12.0$, 5.7, 4.0 Hz), 3.88 (1H, m), 4.17 (1H, m), 5.18 (1H, m), 5.20 (1H, m), 7.15–7.26 (3H, m), 7.27–7.29 (2H, m) ppm; ¹³C NMR (125 MHz, CDCl₃, 0.022 M, 297 K) δ 21.19, 24.77, 25.13, 25.93, 27.25, 31.28, 34.54, 34.72, 35.52, 35.93, 36.87, 36.98, 42.69, 63.72, 64.43, 68.77, 70.57, 71.74, 100.20, 125.52, 128.19 (2C), 128.44 (2C), 142.91, 169.60, 171.51 ppm; HR-FAB-MS m/z 475.2700 ([M+H]⁺). Calcd for C₂₇H₃₉O₇ 475.2696; [α]_D +41 (c 0.218, CHCl₃, 22.7 °C).
- Irie, K.; Oie, K.; Nakahara, A.; Yanai, Y.; Ohigashi, H.; Wender, P. A.; Fukuda, H.; Konishi, H.; Kikkawa, U. *J. Am. Chem. Soc.* **1998**, *120*, 9159.
- Nakamura, H.; Kishi, Y.; Pajares, M. A.; Rando, R. R. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, *86*, 9672.
- Yamori, T. *Cancer Chemother. Pharmacol.* **2003**, *52*, S74.
- Wender, P. A.; Baryza, J. L.; Bennett, C. E.; Bi, F. C.; Brenner, S. E.; Clarke, M. O.; Horan, J. C.; Kan, C.; Lacôte, E.; Lippa, B.; Nell, P. G.; Turner, T. M. *J. Am. Chem. Soc.* **2002**, *124*, 13648.
- Ito, Y.; Yanase, S.; Fujita, J.; Harayama, T.; Takashima, M.; Imanaka, H. *Cancer Lett.* **1981**, *13*, 29.
- Irie, K.; Nakahara, A.; Ikawa, Y.; Tanaka, M.; Nakagawa, Y.; Nakamura, Y.; Ohigashi, H.; Wender, P. A. *Biosci. Biotechnol. Biochem.* **2000**, *64*, 2429.
- Irie, K.; Isaka, T.; Iwata, Y.; Yanai, Y.; Nakamura, Y.; Koizumi, F.; Ohigashi, H.; Wender, P. A.; Satomi, Y.; Nishino, H. *J. Am. Chem. Soc.* **1996**, *118*, 10733.
- Setterblad, N.; Onyango, I.; Pihlgren, U.; Rask, L.; Andersson, G. *J. Immunol.* **1998**, *161*, 4819.
- Kamimura, K.; Hojo, H.; Abe, M. *Pathol. Int.* **2004**, *54*, 224.
- Shindo, M.; Irie, K.; Nakahara, A.; Ohigashi, H.; Konishi, H.; Kikkawa, U.; Fukuda, H.; Wender, P. A. *Bioorg. Med. Chem.* **2001**, *9*, 2073.